Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open-label, phase 3 trial

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

The Lancet

Topics

Biology

Cancer Oncology

Medicine

Paleontology

Internal Medicine

Show all topics

DOI

10.1016/s0140-6736(24)01315-1

License

CC-BY